Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin Standard Treasury halts $4B SPAC merger, opts to remain private amid tough market conditions

Market News
28 Sep 2026
Crypto Briefing
View Source
Neutral
Bitcoin Standard Treasury halts $4B SPAC merger, opts to remain private amid tough market conditions

Bitcoin Standard Treasury Company, led by Adam Back, has canceled its $4 billion SPAC merger with Cantor Equity Partners I, choosing to stay private due to unfavorable market conditions and repeated delays in shareholder votes. The company, which had amassed over 30,000 BTC valued at $3 billion, had planned a major Nasdaq debut but will now pause its public market ambitions. BSTR aims to revisit the merger when market and internal conditions improve, continuing its strategy of active Bitcoin management and yield generation rather than passive holding.

Bitcoin Standard Treasury Company’s decision to stay private comes as a backdrop to broader cryptocurrency market trends. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 29, 2026 02:51 WIB: out of 50 priced major cryptocurrencies, 10 rose and 39 fell today. Notable movers include AXS at Rp19.786 with a 7.22% decline, SUSHI at Rp4.488 down 7.19%, and GRT at Rp540 down 7.17%.

More News

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...

Analyst Insights
Bullish
59 minutes ago
Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...

Analyst Insights
Bullish
1 hour ago
Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...

Market News
Bullish
2 hours ago
Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...

Analyst Insights
Neutral
2 hours ago
Zcash price drops 9.63% in 24 hours, hitting $1,456 amid $6.5M long liquidations.

Zcash price drops 9.63% in 24 hours, hitting $1,456 amid $6.5M long liquidations.

Zcash (ZEC) experienced a significant price decline of 9.63% over 24 hours, falling from $1,520 to $1,456 within one hour on September 28. This drop was accompanied by $6.5 million in long position liquidations across major exchanges Binance, Bybit, ...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App